NCT03440112View on ClinicalTrials.gov

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

December 8, 2021

Study Completion Date

December 8, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Clarithromycin (Not used as of 4/2020)

Clarithromycin (generic) capsule 250mg each

DRUG

Placebo (Not used as of 4/2020)

Lactose in a gel capsule

DRUG

Transdermal flumazenil (Added 4/2020)

Transdermal flumazenil 24mg/mL

DRUG

Placebo (Added 4/2020)

Transdermal placebo

Trial Locations (1)

48106

University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Nicolaas Bohnen, MD, PhD

OTHER

NCT03440112 - Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm | Biotech Hunter | Biotech Hunter